Comparative Pharmacology
Head-to-head clinical analysis: MINIPRESS versus SILODOSIN.
Head-to-head clinical analysis: MINIPRESS versus SILODOSIN.
MINIPRESS vs SILODOSIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective antagonist of postsynaptic alpha-1 adrenergic receptors, inhibiting vasoconstriction and reducing peripheral vascular resistance.
Silodosin is a highly selective antagonist of alpha-1A adrenergic receptors located primarily in the prostate, bladder base, and proximal urethra. Blockade of these receptors relaxes smooth muscle in these tissues, reducing urinary outflow resistance and improving symptoms of benign prostatic hyperplasia (BPH). It has minimal affinity for alpha-1B receptors, thereby reducing the risk of orthostatic hypotension compared to non-selective alpha blockers.
Initial: 1 mg orally 2-3 times daily. Maintenance: 2-5 mg orally 2-3 times daily. Maximum: 20 mg/day.
8 mg orally once daily with a meal.
None Documented
None Documented
Clinical Note
moderateSilodosin + Digoxin
"The serum concentration of Digoxin can be increased when it is combined with Silodosin."
Clinical Note
moderateSilodosin + Levofloxacin
"The serum concentration of Levofloxacin can be increased when it is combined with Silodosin."
Clinical Note
moderateSilodosin + Tranilast
"Silodosin may increase the hypotensive activities of Tranilast."
Clinical Note
moderateSilodosin + Prednisone
Terminal elimination half-life is 2-3 hours; clinical effect persists longer (up to 24 hours) due to sustained receptor binding.
Terminal half-life: 11-13 hours; allows once-daily dosing; prolongation in severe renal impairment
Primarily hepatic metabolism (90%) with <10% excreted unchanged in urine; 50-60% of metabolites eliminated in bile/feces, 40-50% in urine.
Renal (33.5% as unchanged drug, 64.3% as metabolites); fecal (<5%)
Category C
Category A/B
Alpha-1 Blocker
Alpha-1 Blocker
"The serum concentration of Prednisone can be increased when it is combined with Silodosin."